Compare DAVA & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAVA | SENS |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.4M | 213.2M |
| IPO Year | 2015 | 2014 |
| Metric | DAVA | SENS |
|---|---|---|
| Price | $4.16 | $5.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $13.50 | ★ $18.38 |
| AVG Volume (30 Days) | 216.5K | ★ 565.7K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | $4.07 | $58.60 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $3.98 | $0.41 |
| 52 Week High | $20.80 | $8.75 |
| Indicator | DAVA | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 27.46 |
| Support Level | N/A | $0.43 |
| Resistance Level | $7.04 | $8.68 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 17.43 | 2.61 |
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.